Brolucizumab: Difference between revisions
No edit summary |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{Short description|A monoclonal antibody used in the treatment of neovascular age-related macular degeneration}} | ||
| | |||
}} | |||
'''Brolucizumab''' | '''Brolucizumab''' is a humanized single-chain antibody fragment (scFv) used in the treatment of [[neovascular age-related macular degeneration]] (nAMD). It is marketed under the brand name Beovu and was developed by [[Novartis]]. Brolucizumab is designed to inhibit [[vascular endothelial growth factor A]] (VEGF-A), a protein that plays a critical role in the formation of abnormal blood vessels in the eye, which can lead to vision loss. | ||
==Mechanism of Action== | |||
Brolucizumab works by binding to and inhibiting the activity of VEGF-A. VEGF-A is a key mediator of angiogenesis, the process by which new blood vessels form from pre-existing vessels. In nAMD, overexpression of VEGF-A leads to the growth of abnormal blood vessels beneath the [[retina]], causing leakage, bleeding, and scarring. By inhibiting VEGF-A, brolucizumab reduces the growth of these abnormal vessels and decreases fluid leakage, thereby stabilizing or improving vision. | |||
==Clinical Use== | |||
Brolucizumab is administered via intravitreal injection, directly into the [[vitreous humor]] of the eye. The typical dosing regimen involves an initial loading phase of monthly injections for the first three months, followed by maintenance injections every 8 to 12 weeks, depending on the patient's response and the physician's assessment. | |||
==Efficacy and Safety== | |||
Clinical trials have demonstrated that brolucizumab is effective in improving visual acuity and reducing retinal fluid in patients with nAMD. It has been shown to have a similar efficacy to other anti-VEGF therapies, such as [[ranibizumab]] and [[aflibercept]], with the advantage of potentially longer dosing intervals. | |||
The safety profile of brolucizumab is generally consistent with other anti-VEGF agents, with the most common adverse events being conjunctival hemorrhage, eye pain, and vitreous floaters. However, there have been reports of rare but serious adverse events, such as retinal vasculitis and retinal vascular occlusion, which require careful monitoring and management. | |||
== | ==Development and Approval== | ||
Brolucizumab was developed by Novartis and received approval from the [[U.S. Food and Drug Administration]] (FDA) in October 2019 for the treatment of nAMD. It has since been approved in several other countries and is considered a valuable addition to the therapeutic options available for managing this condition. | |||
==Related pages== | |||
* [[Neovascular age-related macular degeneration]] | |||
* [[Vascular endothelial growth factor]] | |||
* [[Monoclonal antibody]] | |||
* [[Intravitreal injection]] | |||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Ophthalmology]] | |||
[[Category:Drugs acting on the sensory organs]] | |||
Latest revision as of 19:08, 22 March 2025
A monoclonal antibody used in the treatment of neovascular age-related macular degeneration
Brolucizumab is a humanized single-chain antibody fragment (scFv) used in the treatment of neovascular age-related macular degeneration (nAMD). It is marketed under the brand name Beovu and was developed by Novartis. Brolucizumab is designed to inhibit vascular endothelial growth factor A (VEGF-A), a protein that plays a critical role in the formation of abnormal blood vessels in the eye, which can lead to vision loss.
Mechanism of Action[edit]
Brolucizumab works by binding to and inhibiting the activity of VEGF-A. VEGF-A is a key mediator of angiogenesis, the process by which new blood vessels form from pre-existing vessels. In nAMD, overexpression of VEGF-A leads to the growth of abnormal blood vessels beneath the retina, causing leakage, bleeding, and scarring. By inhibiting VEGF-A, brolucizumab reduces the growth of these abnormal vessels and decreases fluid leakage, thereby stabilizing or improving vision.
Clinical Use[edit]
Brolucizumab is administered via intravitreal injection, directly into the vitreous humor of the eye. The typical dosing regimen involves an initial loading phase of monthly injections for the first three months, followed by maintenance injections every 8 to 12 weeks, depending on the patient's response and the physician's assessment.
Efficacy and Safety[edit]
Clinical trials have demonstrated that brolucizumab is effective in improving visual acuity and reducing retinal fluid in patients with nAMD. It has been shown to have a similar efficacy to other anti-VEGF therapies, such as ranibizumab and aflibercept, with the advantage of potentially longer dosing intervals.
The safety profile of brolucizumab is generally consistent with other anti-VEGF agents, with the most common adverse events being conjunctival hemorrhage, eye pain, and vitreous floaters. However, there have been reports of rare but serious adverse events, such as retinal vasculitis and retinal vascular occlusion, which require careful monitoring and management.
Development and Approval[edit]
Brolucizumab was developed by Novartis and received approval from the U.S. Food and Drug Administration (FDA) in October 2019 for the treatment of nAMD. It has since been approved in several other countries and is considered a valuable addition to the therapeutic options available for managing this condition.
